IMVT · Immunovant, Inc.
$40.09
-2.97% last session
End-of-day data · updated 2026-07-29
Market cap
$8B
Enterprise value
$7B
Trailing P/E
—
Forward P/E
-19.0
Dividend yield
—
Beta
0.77
Avg volume
2M
Employees
0K
2D change
-2.97%
5D change
—
10D change
-3.38%
30D change
1.01%
60D change
16.82%
MTD change
1.99%
YTD change
53.03%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IMVT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-30
Latest call per bank · past 12 months
Citigroup
Buy$61.00
+52.2% vs priceBank of America
Buy$43.00
+7.3% vs priceGoldman Sachs
Neutral$32.00
-20.2% vs priceJP Morgan
Overweight$33.00
-17.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-30 | Citigroup | Maintains | Buy | $57.00 → $61.00 |
| 2026-05-26 | Guggenheim | Maintains | Buy | $44.00 → $62.00 |
| 2026-05-22 | Truist Securities | Maintains | Hold | $23.00 → $30.00 |
| 2026-05-21 | Bank of America | Maintains | Buy | $32.00 → $43.00 |
| 2026-05-21 | HC Wainwright & Co. | Maintains | Buy | $35.00 → $40.00 |
| 2026-04-15 | Goldman Sachs | Maintains | Neutral | $29.00 → $32.00 |
| 2026-02-10 | HC Wainwright & Co. | Reiterates | Buy | $35.00 |
| 2026-02-09 | Guggenheim | Maintains | Buy | $41.00 → $44.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 54 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.2% above the 50-day MA ($35.63).
- Price vs 200-day MA: Trading 40.9% above the 200-day MA ($27.61).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.33) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($14.69) and high ($41.09).
IMVT Price Chart
Loading chart for IMVT…
Fundamentals
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$124B 8.2% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$73B -9.7% YTD
ARGX
argenx SE
$55B 3.7% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$39B -27.5% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.8% YTD
RPRX
Royalty Pharma plc
$35B 56.7% YTD
ONC
BeOne Medicines Ltd.
$34B 8.8% YTD
INCY
Incyte Corporation
$26B 31.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.